Eli Lilly's (LLY, Financial) development of a once-daily oral GLP-1 medication is showing promising results in matching the effectiveness and safety of Novo Nordisk's (NVO) weekly injectable semaglutide. Notably, reports indicate the absence of any liver-related safety concerns with the oral drug during trials.
Looking ahead, Leerink anticipates the release of the Phase 3 topline results for orforglipron in the third quarter of 2025. The approval of this drug is expected to follow in 2026, which could significantly bolster Eli Lilly's position in the diabetes and weight management market.
In light of these developments, Leerink has reaffirmed its Outperform rating for Eli Lilly’s stock, indicating confidence in the company's potential growth driven by its innovative product pipeline.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 25 analysts, the average target price for Eli Lilly and Co (LLY, Financial) is $1,014.97 with a high estimate of $1,190.00 and a low estimate of $800.00. The average target implies an upside of 19.60% from the current price of $848.67. More detailed estimate data can be found on the Eli Lilly and Co (LLY) Forecast page.
Based on the consensus recommendation from 29 brokerage firms, Eli Lilly and Co's (LLY, Financial) average brokerage recommendation is currently 1.9, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Eli Lilly and Co (LLY, Financial) in one year is $1126.38, suggesting a upside of 32.72% from the current price of $848.67. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Eli Lilly and Co (LLY) Summary page.
